---

Tony Adamis

Vice President and Global Head of Ophthalmology, Genentech.

Anthony Adamis has had two careers in ophthalmology: one as a clinician and a second as an industry executive. One of the team who discovered the role that VEGF plays in retinal neovascularization, Adamis also participated in the development and launch of pegaptanib, the first anti-VEGF agent approved for use in ophthalmology. He was also part of the team who discovered that, in ocular models of neovascular growth, the addition of an anti-PDGF agent to anti-VEGF therapy is more effective than an anti-VEGF agent alone in enhancing vessel regression.

---

Part of the Power List 2016

100 reasons to be proud

Welcome to The Power List 2016 – our second foray into the Top 100 most influential people in the world of ophthalmology.

Though we realize our list can (and should) never be definitive, who can argue that the faces within – both familiar and new – do not beautifully highlight the brilliance and diversity found within the field?

Here, we celebrate 100 reasons to be proud of ophthalmology.

Go to The Power List 2016